傳記

Demir Akin博士是納米生物技術和納米醫學領域的知名專家，也是診斷和治療微/納米製造設備、癌症和傳染病的納米靶向藥物和顯像劑設計和交付領域的跨學科先驅科學家。他的正式教育包括獸醫博士學位、臨床和診斷微生物學碩士學位和病理學和分子病毒學博士學位。他在生物醫學科學方麵有30多年的經驗，在電氣工程(生物傳感器)和醫學納米技術方麵有13年以上的經驗。在前往斯坦福大學醫學院之前，他曾在普渡大學生物醫學工程學院擔任助理研究教授(納米醫學)，在那裏他還管理著Birck納米技術中心的六個生物醫學和納米生物實驗室。Akin博士於2008年加入斯坦福大學放射科，並在過去六年中指導了一個超過3000萬美元的癌症納米技術研究項目。他目前擔任斯坦福癌症納米技術卓越和翻譯中心(CCNE-T;http://mips.stanford.edu/grants/ccne-t, PI: Sanjiv Sam Gambhir, MD, PhD)在斯坦福大學醫學院。該中心由來自國內頂尖大學的傑出納米科學家、工程師和醫生組成，共同致力於解決癌症早期檢測和預測問題，以及利用基於納米技術的體外診斷和醫學成像工具監測癌症治療的反應。在他的早期工作期間，Akin博士在普渡大學(Purdue)核工程學院(School of Nuclear Engineering at Purdue)從事基於人工智能的in - silica生物學和基因組學領域的工作。2002年，他加入了那裏的電氣和計算機工程係，擔任高級科學家，並在Birck納米技術中心的基礎設計、運行和領導方麵發揮了重要作用，直到2008年5月他轉到斯坦福大學(Stanford)。Akin博士在診斷和治療微/納米醫療設備、微芯片和基於生物ems / nems的設備領域進行了研究，這些設備應用於癌症和傳染病檢測，特別是具有大流行/生物威脅潛力的空氣傳播病原體的超靈敏檢測。 Dr. Akin’s current research interests are focused on the development and clinical validation of wearable/implantable micro-fabricated devices for continuous and minimally invasive monitoring of cancer relevant biomarkers (protein, nucleic acid and circulating tumor cells) in bodily fluids, intracellular nanomedical robotics, analysis of cell:cellsignaling in cancer, biomimetic medical devices, and bionics for function restorative medicine. Among many of his distinctions, he is a member of the NCI Alliance for Nanotechnology in Cancer and nanoHub, a founding member of the American Academy of Nanomedicine, a founding member of International Society for Human Simulation, and serves as panelist on numerous grant and scientific review boards nationally and internationally as well as being an editorial board member of twojournals. Dr. Akin has also contributed to two very important U.S. National Nanotechnology Policy Recommendations and Plans: a) Cancer Nanotechnology Plan 2010-2020. National Cancer Institute, NIH (this landmark plan outlines the next 10-year national goals and milestones for the use of nanotechnology in cancer); b)Nanotechnology Research Directions for Societal Needs in 2020, National Science Foundation (this important publication lays the groundwork for phase 2 of the U.S. National Nanotechnology Initiative, outlining the visions until 2020, assesses the needs and offers recommendations for the use of nanotechnology in biology and medicine).Dr. Akin is open for collaborationsaround the areas listed above and can be contacted by one of the means below.